Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Current Leases for 4 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 38.69% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 38.69% year-over-year, with the annual reading at $2.5 million for FY2025, 38.69% up from the prior year.
  • Current Leases hit $2.5 million in Q4 2025 for Axsome Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.5 million in Q4 2025 to a low of $108000.0 in Q1 2023.
  • Historically, Current Leases has averaged $1.1 million across 4 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Current Leases: plummeted 88.83% in 2023 and later skyrocketed 967.59% in 2024.
  • Year by year, Current Leases stood at $425000.0 in 2022, then soared by 198.12% to $1.3 million in 2023, then surged by 44.83% to $1.8 million in 2024, then surged by 38.69% to $2.5 million in 2025.
  • Business Quant data shows Current Leases for AXSM at $2.5 million in Q4 2025, $2.5 million in Q3 2025, and $2.0 million in Q2 2025.